To include your compound in the COVID-19 Resource Center, submit it here.

First Phase III data for Mimetogen's dry eye compound

Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) reported top-line data from a Phase III trial of MIM-D3 for dry eye,

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE